# A Study of the Efficacy and Safety of Ulipristal Acetate Intermittent Treatment for Abnormal Uterine Bleeding Associated With Leiomyomas

> **NCT02147158** · PHASE3 · COMPLETED · sponsor: **Allergan** · enrollment: 432 (actual)

## Conditions studied

- Leiomyoma
- Uterine Hemorrhage

## Interventions

- **DRUG:** Ulipristal acetate (UPA)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02147158
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01-29
- **Primary completion:** 2016-11-24
- **Final completion:** 2016-11-24
- **Target enrollment:** 432 (ACTUAL)
- **Last updated:** 2019-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02147158

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02147158, "A Study of the Efficacy and Safety of Ulipristal Acetate Intermittent Treatment for Abnormal Uterine Bleeding Associated With Leiomyomas". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02147158. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*